larg
major
approv
drug
act
protein
target
chemic
divers
set
clinic
import
antibiot
bind
select
rna
compon
rrna
bacteri
ribosom
therebi
interfer
protein
antibiot
deriv
natur
product
provid
paradigm
target
structur
noncod
rna
approach
therapeut
intervent
noncod
rna
ncrna
molecul
increasingli
recogn
key
regulatori
player
biolog
particip
base
structur
rather
sequenc
structur
ncrna
fold
provid
potenti
uniqu
interact
site
select
ligand
affect
rna
biolog
function
outsid
bacteri
ribosom
untransl
rna
region
drug
target
pursu
discov
therapeut
viral
infect
includ
caus
human
immunodefici
viru
hiv
hepat
c
viru
hcv
pathogen
rna
genom
includ
structur
noncod
region
play
key
role
viral
infect
cycl
harbor
potenti
bind
site
small
molecul
inhibitor
high
conserv
untransl
region
viral
genom
along
absenc
homolog
host
cell
rna
render
structur
viral
regulatori
rna
attract
target
develop
novel
antiinfect
unlik
typic
inhibitor
bind
pocket
protein
site
ligand
recognit
rna
often
shallow
highli
solvat
conform
flexibl
therefor
structur
physicochem
properti
small
molecul
ligand
rna
differ
markedli
drug
target
clinic
use
antibiot
deriv
natur
product
averag
structur
complex
hydrophil
contain
larger
number
hydrogen
bond
donor
compar
molecular
properti
creat
challeng
reconcil
design
optim
ligand
featur
affect
absorpt
distribut
vivo
strategi
design
discoveri
ligand
outlin
long
rise
comprehens
review
target
rna
small
molecul
publish
regularli
last
among
chemic
divers
class
rna
recur
scaffold
found
among
deriv
aminoglycosid
planar
intercal
includ
acridin
phenothiazin
figur
aminoglycosid
natur
product
streptomyc
soil
bacteria
bind
ribosom
decod
site
exert
antibiot
activ
interf
bacteri
protein
amin
function
group
aminoglycosid
proton
physiolog
condit
result
overal
cation
charg
promot
nucleic
acid
bind
hamper
cell
penetr
aminoglycosid
deriv
report
promiscu
bind
numer
ncrna
includ
regulatori
element
hiv
two
decad
ago
first
viral
rna
investig
suggest
aminoglycosid
bind
rna
fold
structur
electrostat
complementar
wherebi
posit
charg
ammonium
group
ligand
recogn
pocket
creat
rna
similarli
promiscu
bind
structur
rna
observ
intercal
compound
contain
flat
aromat
scaffold
acridin
phenazin
phenothiazin
deriv
earli
studi
ncrna
focus
proof
concept
often
involv
promiscu
binder
includ
aminoglycosid
intercal
recent
consider
compound
promin
includ
rna
target
effort
drug
oxazolidinon
antibiot
provid
compel
remind
properti
benefici
may
reconcil
within
small
molecul
compound
figur
focu
progress
last
year
discoveri
investig
small
molecul
ligand
viral
rna
target
emphasi
given
ligand
molecular
weight
coverag
literatur
occasion
go
back
time
previous
report
compound
class
recent
work
reveal
new
find
mechan
action
provid
structur
insight
review
recent
discov
ligand
target
viral
rna
includ
discuss
compound
physicochem
properti
affect
rna
genom
hiv
contain
multipl
regulatori
element
involv
transcript
regul
revers
transcript
viral
protein
translat
nucleocytoplasm
transport
genom
dimer
virion
tar
element
resid
within
first
nucleotid
viral
genom
serv
bind
site
tat
protein
format
tattar
complex
stimul
transcript
elong
yield
transcript
complex
mechan
also
involv
host
cell
site
tar
consist
conserv
rna
bulg
figur
conform
dynam
adopt
stabl
order
structur
complex
tat
peptid
small
molecul
ligand
disrupt
tattar
complex
compet
ligand
bind
rna
target
block
effici
hiv
replic
recogn
earli
potenti
path
develop
antivir
numer
studi
focus
discoveri
design
tar
inhibitor
includ
peptid
natur
product
aminoglycosid
synthet
small
molecul
earlier
effort
summar
sever
excel
recent
schneekloth
cowork
appli
small
molecul
microarray
smm
screen
fluoresc
label
tar
hairpin
model
oligonucleotid
identifi
select
similar
approach
taken
disney
seeberg
explor
interact
aminoglycosid
ribosom
group
intron
ribozym
recent
studi
hiv
tar
screen
librari
compos
small
molecul
bias
chemotyp
consid
promot
rna
bind
appli
unrel
rna
hairpin
exclud
promiscu
binder
smm
screen
return
low
hit
rate
excel
low
rate
eventu
deliv
confirm
hit
compound
tabl
reason
properti
activ
valu
well
low
cytotox
thienopyridin
deriv
surprisingli
hydrophob
ligand
similar
chemotyp
report
remain
seen
potenc
thienopyridin
deriv
improv
furnish
lead
candid
develop
antivir
drug
target
hiv
tar
nevertheless
smm
screen
approach
proven
promis
method
discoveri
ligand
rna
fruit
applic
ncrna
target
expect
screen
approach
identifi
ligand
hiv
tar
element
describ
colleagu
interrog
set
small
molecul
select
repres
molecular
motif
benefici
rna
fragment
rich
chemotyp
provid
hydrogen
bond
donor
includ
amin
amidin
guanidin
well
benzen
ring
stack
interact
fluorimetr
competit
assay
box
use
determin
ligand
bind
test
abil
compound
displac
tat
peptid
tar
model
rna
seven
small
molecul
screen
set
found
compet
tat
peptid
bind
tar
valu
includ
quinazolin
shown
exampl
tabl
valu
least
two
hit
compound
identifi
previous
inhibitor
tattar
complex
format
shown
downregul
tat
transactiv
cellular
activ
test
fragment
screen
approach
report
et
al
nmr
use
confirm
ligand
interact
rna
target
monitor
chang
signal
upon
titrat
compound
consequ
composit
bia
screen
set
small
molecul
rich
hydrogen
bond
donor
hit
compound
tend
exceed
number
hydrogen
bond
donor
typic
molecul
howev
fragment
incorpor
construct
larger
ligand
futur
would
reduc
number
hydrogen
bond
donor
site
benhida
cowork
pursu
design
approach
tar
ligand
base
nucleobas
analog
propos
interact
pair
hydrogen
bond
scaffold
hoogsteen
edg
set
conjug
scaffold
term
nucleobas
highlight
blue
compound
tabl
differ
natur
amino
acid
dipeptid
synthes
test
rna
target
bind
well
antivir
activ
cell
cultur
consequ
design
paradigm
focus
scaffold
interact
result
compound
hydrophil
carri
larger
number
hydrogen
bond
donor
group
ligand
tar
element
identifi
monitor
fluoresc
chang
upon
compound
titrat
termin
tar
model
oligonucleotid
box
nucleobas
conjug
arginin
lysin
histidin
found
tightli
bind
tar
rna
howev
histidin
deriv
tabl
select
tar
binder
k
whose
affin
target
diminish
presenc
nucleic
acid
arginin
lysin
conjug
show
better
interact
tar
rna
k
respect
bind
promiscu
strongli
affect
presenc
competitor
nucleic
acid
perhap
attest
correl
target
select
biolog
activ
histidin
deriv
show
antivir
activ
human
cell
clear
viral
inhibit
potenc
exce
target
bind
affin
find
suggest
howev
compound
may
act
target
addit
tar
rna
among
recent
describ
structur
complex
ligand
tar
rna
whose
molecular
weight
exce
conjug
develop
arya
appella
aminoglycosid
synthes
hamasaki
aminoglycosid
conjug
seri
highli
hydrophil
compound
contain
hydrogen
bond
donor
nanomolar
affin
tar
target
antivir
activ
conjug
compound
cell
report
hiv
rre
element
locat
within
stretch
approxim
nucleotid
second
intron
viral
genom
rna
complex
structur
tar
motif
iib
form
residu
rre
figur
serv
bind
site
viral
rev
protein
rev
bind
rre
requir
nucleocytoplasm
export
singli
splice
viral
transcript
disrupt
interact
explor
two
decad
strategi
develop
antivir
therapi
past
effort
discov
ligand
rre
rna
larg
focus
design
summar
comprehens
two
studi
publish
small
molecul
screen
inhibitor
target
none
approach
yet
produc
bona
fide
inhibitor
vitro
complex
format
show
antivir
activ
cell
recent
studi
rana
colleagu
shown
modif
rre
adenin
base
play
critic
role
activ
rrerev
serv
poignant
remind
authent
model
system
requisit
studi
rna
target
gallego
cowork
identifi
inhibitor
hiv
rna
biogenesi
block
interact
bind
competit
screen
box
drug
complex
format
fluoresc
label
rev
peptid
rre
rna
antivir
activ
hit
compound
cell
confirm
clomiphen
tabl
cyproheptadin
inhibit
hiv
transcript
affect
level
splice
versu
unsplic
viral
transcript
extent
consist
abil
disrupt
complex
function
vitro
clomiphen
select
estrogen
receptor
modul
inhibit
rev
peptid
bind
rre
valu
antivir
activ
valu
assay
correspond
valu
cyproheptadin
antihistamin
receptor
antagonist
interact
clomiphen
highli
specif
rre
target
target
bind
cyproheptadin
significantli
compromis
presenc
competitor
trna
dna
nmr
spectroscop
studi
reveal
intern
loop
lower
stem
interact
site
overlap
bind
region
rev
consist
propos
mechan
inhibit
ligand
competit
direct
interact
hydrophob
drug
rna
target
may
appear
unexpect
dispel
notion
larg
number
hydrogen
bond
donor
acceptor
requir
confer
properti
small
molecul
ligand
hydrogen
bond
donor
absent
either
compound
translat
hcv
genom
rna
driven
ire
element
recruit
ribosom
directli
viral
start
codon
without
need
host
cell
initi
factor
uniqu
role
viral
ire
high
conserv
clinic
isol
led
recognit
ncrna
potenti
drug
high
throughput
screen
compound
inhibit
ire
function
report
translat
assay
led
discoveri
phenazin
biaryl
moder
select
viral
translat
target
structur
compound
chemic
seri
suggest
may
interact
ire
rna
target
bind
antivir
activ
report
earli
studi
import
breakthrough
achiev
seth
colleagu
use
mass
screen
compound
identifi
deriv
ligand
bind
intern
loop
rna
subdomain
iia
hcv
ire
figur
lead
optim
driven
relationship
data
furnish
compound
tabl
affin
k
ire
target
determin
mass
spectrometri
inhibit
hcv
cell
cultur
valu
show
cytotox
mechan
action
studi
reveal
compound
act
alloster
inhibitor
rna
conform
switch
ire
subdomain
contrast
riboswitch
hcv
ire
subdomain
iia
motif
repres
new
class
rna
conform
switch
structur
bound
state
may
repres
simplest
form
pure
mechan
switch
nucleic
synthet
benzimidazol
fortuit
ligand
recognit
site
captur
subdomain
iia
target
extend
conform
block
viral
translat
initi
ire
element
crystallographi
provid
structur
insight
conform
state
subdomain
iia
switch
inhibitor
ligand
extend
conform
switch
bound
inhibitor
encapsul
deep
rna
pocket
resembl
ligand
interact
site
aptam
riboswitch
figur
b
c
depth
structur
complex
physicochem
properti
ligand
bind
pocket
distinguish
ire
iia
switch
viral
rna
target
suggest
discoveri
inhibitor
feasibl
assay
box
develop
investig
ligand
bind
subdomain
iia
screen
viral
translat
inhibitor
captur
rna
switch
extend
differ
assay
monitor
fluoresc
chang
nucleosid
analog
box
incorpor
intern
loop
subdomain
iia
diaminopiperidin
compound
tabl
found
bind
ire
target
unlik
diaminopiperidin
ligand
lock
rna
conform
switch
bent
state
therebi
inhibit
viral
translat
initi
recent
review
summar
comprehens
studi
diaminopiperidin
hcv
translat
diaminopiperidin
hydrophil
compound
contain
numer
hydrogen
bond
donor
suggest
polar
interact
play
import
role
rna
target
recognit
consequ
bind
affin
compound
subdomain
iia
rna
target
decreas
ionic
strength
contrast
inhibitor
properti
contain
basic
amino
group
posit
charg
physiolog
condit
moreov
construct
pyran
ring
requir
lengthi
synthet
rout
hamper
deep
explor
chemic
recent
design
second
gener
ligand
guanosin
bind
pocket
hcv
ire
subdomain
iia
target
address
shortcom
origin
deriv
approach
maintain
nonplanar
benzimidazol
ligand
introduc
carbon
center
pyran
ring
ligand
design
aryl
deriv
repres
compound
steric
hindranc
aryl
substitu
induc
twist
conform
overal
nonplanar
shape
result
anoth
set
analog
replac
basic
imidazol
ring
first
gener
ligand
less
basic
oxazol
result
ligand
exemplifi
compound
access
straightforward
synthet
rout
display
good
properti
howev
none
synthes
aryl
oxazol
affin
iia
rna
superior
origin
best
ligand
new
compound
seri
show
valu
target
bind
comput
molecular
dynam
md
studi
complex
ire
iia
rna
inspir
design
tetracycl
dipyrroloindol
propos
rigid
less
basic
ligand
howev
synthesi
test
silico
design
compound
report
structur
plastic
hcv
ire
subdomain
iia
illustr
challeng
face
comput
approach
rna
target
gener
larg
conform
chang
iia
rna
target
upon
ligand
bind
accompani
extens
rearrang
base
stack
unexpect
like
beyond
predict
abil
current
comput
approach
rel
success
md
studi
reproduc
conform
rearrang
benzimidazol
ligand
bind
iia
may
attribut
fact
experiment
waypoint
form
crystal
structur
avail
guid
calcul
challeng
larg
conform
chang
rna
target
compound
domin
electrostat
interact
anion
polym
concurr
impact
bind
recogn
achil
heel
comput
approach
review
focus
small
molecul
ligand
molecular
weight
brief
mention
made
metallopeptid
develop
target
domain
hcv
ire
damag
rna
peptid
contain
conserv
acid
motif
coordin
cu
link
recognit
sequenc
confer
rna
target
bind
specif
amino
acid
report
bind
ire
domain
inhibit
hcv
cell
cultur
submicromolar
program
ribosom
frameshift
evolutionari
strategi
maxim
code
content
genom
provid
mechan
allow
translat
overlap
read
rna
virus
includ
hiv
sever
acut
respiratori
syndrom
cov
sar
cov
regul
transit
highli
express
structur
protein
viral
enzym
express
low
level
frameshift
translat
translat
frameshift
trigger
interplay
two
rna
motif
includ
slipperi
sequenc
read
frame
chang
occur
follow
structur
region
stall
ribosom
structur
frameshift
motif
hiv
consist
long
rna
hairpin
intern
loop
explor
ligand
target
approach
aim
stabil
disrupt
rna
fold
earlier
studi
hiv
target
discuss
recent
comprehens
review
le
grice
sar
cov
translat
viral
protein
requir
replic
includ
rna
polymeras
initi
program
frameshift
trigger
rna
pk
figur
park
colleagu
use
silico
screen
approach
identifi
ligand
sar
cov
sinc
structur
target
determin
yet
dock
compound
perform
model
rna
pk
among
hit
compound
identifi
screen
deriv
mtdb
tabl
report
inhibitor
translat
frameshift
vitro
assay
direct
interact
sar
cov
pk
demonstr
recent
ritchi
cowork
measur
ligand
bind
rna
target
surfac
plasmon
reson
spr
determin
k
went
perform
unfold
experi
pk
absenc
presenc
led
conclus
ligand
bind
reduc
conform
plastic
rna
fold
therebi
affect
ribosom
frameshift
effici
frameshift
determin
thermodynam
stabil
pk
impact
ribosom
paus
rather
abil
rna
fold
adopt
altern
conform
therefor
ligand
bind
may
affect
translat
frameshift
complex
mechan
partial
reli
stabil
pk
rna
previous
identifi
inhibitor
hiv
translat
frameshift
suggest
promiscu
abil
may
affect
ribosom
rna
rather
viral
genom
frameshift
interact
multipl
target
may
play
role
inhibitori
action
well
may
account
higher
potenc
compound
frameshift
inhibitor
compar
rna
bind
influenza
orthomyxoviru
harbor
rna
genom
contain
eight
segment
vrna
encod
viral
protein
use
templat
transcript
mrna
replic
complementari
strand
crna
viral
rna
polymeras
partial
duplex
structur
form
circular
vrna
hybrid
conserv
nucleotid
end
result
rna
duplex
figur
stabl
physiolog
serv
promot
transcript
replic
investig
rna
promot
structur
nmr
reveal
bifurc
interact
uracil
base
hydrogen
bond
two
consecut
adenin
residu
opposit
motif
conjunct
neighbor
noncanon
aoc
base
pair
induc
widen
major
groov
rna
promot
helix
near
polymeras
initi
site
sinc
uniqu
structur
featur
introduc
intern
loop
noncanon
base
pair
previous
shown
provid
ligand
recognit
site
duplex
rna
conceiv
select
compound
bind
influenza
rna
promot
might
interfer
polymeras
interact
prevent
viral
replic
inhibitor
interfer
viral
gene
express
bind
rna
promot
would
provid
novel
mechan
action
develop
drug
earlier
studi
choi
cowork
use
competit
assay
fluoresc
label
binder
box
test
aminoglycosid
bind
influenza
rna
affin
low
micromolar
rang
k
report
variou
aminoglycosid
impact
ligand
bind
promot
function
investig
recent
varani
cowork
perform
fragment
bind
screen
compound
oligonucleotid
model
influenza
rna
promot
figur
among
seven
initi
hit
compound
led
chang
rna
imino
proton
signal
observ
nmr
dpq
tabl
highest
affin
k
nmr
spectroscopi
use
obtain
model
promot
complex
figur
b
c
ligand
bind
observ
widen
rna
major
groov
intern
loop
form
bifurc
u
aa
motif
nmr
model
promot
complex
suggest
interact
rna
target
mainli
contact
methoxi
substitu
posit
close
residu
intern
loop
motif
figur
c
research
point
methoxi
group
proton
within
hydrogen
bond
distanc
hydrogen
bond
format
involv
donor
interact
oxygen
nitrogen
acceptor
unusu
preced
biomolecular
interact
weak
may
rare
small
molecul
recognit
rna
fold
hydrogen
bond
involv
donor
observ
contribut
bind
ligand
crystal
structur
purin
sever
natur
product
antibiot
contain
group
includ
anisomycin
crystal
structur
complex
avail
howev
diffract
resolut
data
use
obtain
structur
limit
conclus
potenti
hydrogen
bond
interact
methoxi
group
emetin
antiprotozo
drug
bind
eukaryot
ribosom
contain
compar
recent
structur
plasmodium
ribosom
complex
emetin
show
group
orient
away
rna
howev
limit
resolut
assay
measur
cytopath
effect
inhibit
demonstr
antivir
activ
rna
compound
strain
influenza
well
influenza
b
valu
respect
direct
viral
replic
assay
monitor
luciferas
report
express
modifi
influenza
viru
compound
inhibit
replic
valu
report
later
time
cytotox
detect
compound
concentr
studi
bottini
colleagu
synthes
test
analog
among
analog
set
four
structur
relat
compound
b
c
tabl
stood
improv
bind
affin
influenza
rna
promot
target
k
nmr
activ
inhibitor
viral
replic
author
note
possibl
direct
inhibit
viral
rna
polymeras
deriv
rule
yet
investig
none
compound
show
cytotox
maximum
test
concentr
virus
compact
highli
streamlin
genom
provid
limit
number
protein
target
therapeut
intervent
viral
infect
repertoir
drug
target
may
expand
target
structur
rna
element
genom
transcript
viral
pathogen
review
discuss
recent
progress
discoveri
small
approach
direct
structur
rna
motif
genom
hiv
hcv
sar
cov
influenza
repres
varieti
viru
famili
regulatori
sequenc
viral
genom
transcript
stand
conserv
clinic
isol
promis
high
barrier
resist
develop
inhibitor
target
structur
rna
element
nevertheless
criteria
drugabl
thought
appli
select
rna
target
small
molecul
develop
novel
antivir
therapi
consider
import
ever
light
unpreced
surg
new
ncrna
speci
emerg
key
particip
biolog
structur
deep
ligand
bind
pocket
rare
rna
fold
provid
promis
opportun
discoveri
inhibitor
par
drug
target
viral
protein
among
viral
rna
motif
discuss
hcv
ire
subdomain
iia
perhap
best
embodi
advantag
characterist
drug
target
also
uniqu
respect
function
conform
switch
harbor
proper
ligand
bind
pocket
similar
rna
switch
motif
discov
howev
none
rise
level
threat
human
pathogen
compar
hcv
outsid
virus
compar
deepli
encapsul
ligand
bind
pocket
rna
found
bacteri
riboswitch
exploit
target
antibiot
lesson
effort
ligand
discoveri
structur
rna
element
includ
regulatori
motif
virus
discuss
bacteri
rrna
riboswitch
ncrna
may
inspir
futur
search
inhibitor
target
rna
motif
wider
rang
virus
tabl
list
select
virus
high
human
diseas
burden
structur
rna
element
shown
play
role
infect
flavivirus
includ
dengu
west
nile
zika
virus
harbor
rna
motif
involv
replic
translat
control
host
sever
flaviviru
rna
element
featur
conserv
structur
complex
compar
viral
rna
motif
discuss
review
may
tractabl
target
small
molecul
ligand
discoveri
varieti
potenti
drug
target
structur
rna
element
also
found
filovirus
includ
etiolog
agent
ebola
marburg
hemorrhag
fever
replic
rna
virus
reli
structur
rna
promot
element
consist
larg
hairpin
involv
nucleotid
terminu
viral
genom
whose
secondari
structur
establish
chemic
terminu
filoviru
genom
interact
end
unlik
rna
promot
influenza
viru
also
ssrna
genom
filoviru
genom
consist
nonseg
rna
encod
read
frame
seven
structur
protein
separ
long
intergen
region
igr
igr
viru
protein
suggest
fold
structur
includ
complex
rna
transcript
viral
gene
involv
nucleocapsid
protein
factor
bind
hairpin
loop
transcript
start
viral
transcript
long
utr
element
deriv
igr
contain
hairpin
loop
structur
may
play
role
transcript
regul
translat
exampl
attract
rna
target
ligand
inhibit
also
found
dna
virus
among
oncogen
kaposi
sarcoma
associ
herpesviru
kshv
common
caus
malign
aid
patient
translat
viral
homolog
flice
inhibitori
protein
vflip
key
player
involv
initi
ire
element
adopt
complex
rna
secondari
structur
includ
conserv
segment
function
chemic
probe
analysi
vflip
ire
reveal
independ
fold
rna
core
domain
link
flexibl
link
hairpin
motif
provid
sever
structur
site
ligand
kshv
also
encod
nucleotid
polyadenyl
nuclear
pan
ncrna
abund
transcript
produc
viral
genom
lytic
pan
rna
essenti
viral
propag
accumul
reli
posttranscript
stabil
involv
rna
motif
act
enhanc
nuclear
retent
element
ene
ene
nucleotid
motif
pan
terminu
sequest
ci
pan
poli
tail
uniqu
tripl
helix
structur
protect
ncrna
decay
lead
accumul
ene
hairpin
structur
contain
larg
intern
loop
tripl
helix
complex
potenti
target
small
molecul
ligand
may
interfer
kshv
replic
one
final
exampl
tractabl
rna
target
dna
viru
pregenom
rna
pgrna
hepat
b
viru
hbv
serv
intermedi
templat
viral
replic
revers
prior
revers
transcript
hbv
pgrna
sequest
togeth
polymeras
subvir
particl
encapsid
initi
revers
transcriptas
requir
conserv
sequenc
termin
region
pgrna
fold
stem
loop
structur
intern
loop
refer
epsilon
encapsid
small
molecul
ligand
rna
motif
report
yet
rna
decoy
epsilon
sequenc
develop
sequest
revers
transcriptas
provid
disrupt
interact
suppress
hbv
conclus
prevent
vaccin
drug
target
viral
protein
polymeras
proteas
proven
rout
antivir
therapi
structur
rna
motif
viral
genom
transcript
provid
new
opportun
expand
repertoir
target
develop
antiinfect
therapi
select
viral
structur
rna
element
inhibitor
discoveri
requir
critic
evalu
properti
defin
target
ligand
protein
particip
key
player
diseas
process
unyield
develop
small
molecul
inhibitor
structur
rna
element
amen
target
low
molecular
weight
ligand
current
known
target
space
biolog
activ
small
molecul
natur
product
sourc
guidanc
rna
target
certainli
appear
among
low
hang
fruit
drug
discoveri
nevertheless
area
antiinfect
drug
provid
strong
record
success
exampl
inhibitor
bacteri
ribosom
target
half
natur
product
known
exhibit
antibiot
activ
major
compound
interact
predominantli
rrna
compon
bacteri
ribosom
loom
larg
paradigm
structur
rna
provid
valuabl
target
antiinfect
drug
recent
bacteri
riboswitch
rna
identifi
unbias
phenotyp
screen
target
new
class
antibiot
lead
wonder
exampl
modern
antibiot
discoveri
promis
excit
futur
rna
target
emerg
explor
novel
therapi
bacteri
viral
infect
